Switch theme
Sign up to access all valuation multiples
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
2014
143
LTM Revenue $0.2M
LTM EBITDA -$292M
$754M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Viridian Therapeutics has a last 12-month revenue (LTM) of $0.2M and a last 12-month EBITDA of -$292M.
In the most recent fiscal year, Viridian Therapeutics achieved revenue of $0.3M and an EBITDA of -$266M.
Viridian Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Viridian Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$292M | XXX | -$266M | XXX | XXX | XXX |
| EBITDA Margin | -117099% | XXX | -88200% | XXX | XXX | XXX |
| EBIT | -$338M | XXX | -$299M | XXX | XXX | XXX |
| EBIT Margin | -135669% | XXX | -99018% | XXX | XXX | XXX |
| Net Profit | -$314M | XXX | -$270M | XXX | XXX | XXX |
| Net Margin | -125955% | XXX | -89387% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Viridian Therapeutics's stock price is $14.
Viridian Therapeutics has current market cap of $1.2B, and EV of $754M.
See Viridian Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $754M | $1.2B | XXX | XXX | XXX | XXX | $-3.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Viridian Therapeutics has market cap of $1.2B and EV of $754M.
Viridian Therapeutics's trades at 2497.1x EV/Revenue multiple, and -2.8x EV/EBITDA.
Equity research analysts estimate Viridian Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Viridian Therapeutics has a P/E ratio of -3.8x.
See valuation multiples for Viridian Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $754M | XXX | $754M | XXX | XXX | XXX |
| EV/Revenue | 3027.3x | XXX | 2497.1x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBIT | -2.2x | XXX | -2.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.8x | XXX | -4.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialViridian Therapeutics's last 12 month revenue growth is 9176%
Viridian Therapeutics's revenue per employee in the last FY averaged $2K, while opex per employee averaged $2.1M for the same period.
Viridian Therapeutics's rule of 40 is -65781% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Viridian Therapeutics's rule of X is -94158% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Viridian Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9176% | XXX | 1133% | XXX | XXX | XXX |
| EBITDA Margin | -117099% | XXX | -88200% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -65781% | XXX | -79023% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -94158% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 78892% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 99118% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Viridian Therapeutics acquired XXX companies to date.
Last acquisition by Viridian Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Viridian Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Viridian Therapeutics founded? | Viridian Therapeutics was founded in 2014. |
| Where is Viridian Therapeutics headquartered? | Viridian Therapeutics is headquartered in United States of America. |
| How many employees does Viridian Therapeutics have? | As of today, Viridian Therapeutics has 143 employees. |
| Who is the CEO of Viridian Therapeutics? | Viridian Therapeutics's CEO is Mr. Stephen Mahoney. |
| Is Viridian Therapeutics publicy listed? | Yes, Viridian Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Viridian Therapeutics? | Viridian Therapeutics trades under VRDN ticker. |
| When did Viridian Therapeutics go public? | Viridian Therapeutics went public in 2014. |
| Who are competitors of Viridian Therapeutics? | Similar companies to Viridian Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Viridian Therapeutics? | Viridian Therapeutics's current market cap is $1.2B |
| What is the current revenue of Viridian Therapeutics? | Viridian Therapeutics's last 12 months revenue is $0.2M. |
| What is the current revenue growth of Viridian Therapeutics? | Viridian Therapeutics revenue growth (NTM/LTM) is 9176%. |
| What is the current EV/Revenue multiple of Viridian Therapeutics? | Current revenue multiple of Viridian Therapeutics is 3027.3x. |
| Is Viridian Therapeutics profitable? | Yes, Viridian Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Viridian Therapeutics? | Viridian Therapeutics's last 12 months EBITDA is -$292M. |
| What is Viridian Therapeutics's EBITDA margin? | Viridian Therapeutics's last 12 months EBITDA margin is -117099%. |
| What is the current EV/EBITDA multiple of Viridian Therapeutics? | Current EBITDA multiple of Viridian Therapeutics is -2.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
